NEWPORT NEWS, Va., July 10, 2012 /PRNewswire/ -- According to a new study by Korean researchers at the Ewha Women's Hospital in Seoul, published this year in the Annals of Nuclear Medicine, Molecular Breast Imaging (MBI), also known as BSGI, may be a better choice than MRI for women who have a new cancer diagnosis and dense breast tissue detected by mammography. According to their results, MBI/BSGI and MRI had nearly the same sensitivity for the detection of additional malignant tumors, but MBI/BSGI was much less likely to be positive in benign lesions.
In their work, Dr. Kim and his colleagues evaluated 66 patients who had a new breast cancer diagnosis and a reported mammography breast density of greater than 50% with MBI/BSGI and MRI prior to surgery. Both MBI/BSGI and MRI detected disease not seen by mammography, however, the MBI/BSGI was more accurate than MRI in determining if lesions were benign or malignant. Only 26% of the additional lesions detected by MRI were malignant compared to MBI/BSGI where 76% of the lesions detected were malignant. This is important for the newly diagnosed breast cancer patient since biopsy is required when imaging studies are positive. Therefore, MBI/BSGI could have led to a large decrease in the number of unnecessary biopsies for women in this trial. According to Dr. Kim, "The results of this study suggest that MBI/BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts."
About Dilon Diagnostics
Dilon Diagnostics®, a brand of Dilon Technologies® Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform MBI/BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering MBI/BSGI to their patients, such as Cornell University Medical Center, New York and George Washington University Medical Center, Washington, D.C. As part of Dilon's commitment to offering complete solutions, the new declipseSPECT is the first intra-operative handheld 3D image viewing and navigation solution with applications in SLNB breast, I-125 Seed Localization, SLNB Head and Neck etc. For more information on Dilon Technologies® please visit www.molecularbreastimaging.com
Media contact: Pjerin Luli
|SOURCE Dilon Diagnostics|
Copyright©2012 PR Newswire.
All rights reserved